[
  {
    "title": "止盈转亏 三生国健2022年半年度净亏损718.94万元",
    "href": "http://stock.jrj.com.cn/2022/08/25091336934025.shtml",
    "datetime": "2022-08-25 09:13:43",
    "code": "688336"
  },
  {
    "title": "三生国健2022年第一季度净利34.93万同比扭亏为盈 销售费用及研发费用减少",
    "href": "http://stock.jrj.com.cn/2022/05/03175036545444.shtml",
    "datetime": "2022-05-03 17:50:49",
    "code": "688336"
  },
  {
    "title": "一图看懂三生国健(688336.SH)2021年度业绩亮点",
    "href": "http://stock.jrj.com.cn/2022/03/30144236193710.shtml",
    "datetime": "2022-03-30 14:42:39",
    "code": "688336"
  },
  {
    "title": "三生国健2021年净利1805.85万同比扭亏为盈 董事长LOU JING薪酬60.18万",
    "href": "http://stock.jrj.com.cn/2022/03/29145236127864.shtml",
    "datetime": "2022-03-29 14:52:40",
    "code": "688336"
  },
  {
    "title": "三生国健去年净利润1806万元：市场推广费1.3亿元",
    "href": "http://stock.jrj.com.cn/2022/03/29113136093833.shtml",
    "datetime": "2022-03-29 11:31:37",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：SSGJ-617注射液晚期实体瘤临床试验获批",
    "href": "http://stock.jrj.com.cn/2022/03/22160034860831.shtml",
    "datetime": "2022-03-22 16:00:20",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗IL-1β人源化单克隆抗体注射液获批开展急性痛风性关节炎临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/11171134814426.shtml",
    "datetime": "2022-03-11 17:11:14",
    "code": "688336"
  },
  {
    "title": "什么情况？百亿肿瘤药公司连发公告，首席科学家离职，肿瘤领域布局恐生变数……",
    "href": "http://stock.jrj.com.cn/2022/01/13201034155409.shtml",
    "datetime": "2022-01-13 20:10:05",
    "code": "688336"
  },
  {
    "title": "三生国健2021年预计净利1800万-2200万同比扭亏为盈 销售收入相应增加",
    "href": "http://stock.jrj.com.cn/2022/01/12191434150972.shtml",
    "datetime": "2022-01-12 19:14:22",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)2021年度业绩预告：实现扭亏为盈、营收增长37.4%-52.67%及研发费用增速达23.44%-41.07%",
    "href": "http://stock.jrj.com.cn/2022/01/12164234150143.shtml",
    "datetime": "2022-01-12 16:42:14",
    "code": "688336"
  },
  {
    "title": "三生国健两宗信披违规 收上海证监局警示函",
    "href": "http://stock.jrj.com.cn/2022/01/05105134123308.shtml",
    "datetime": "2022-01-05 10:51:00",
    "code": "688336"
  },
  {
    "title": "三生国健：SSGJ-706注射液获批开展相关临床试验",
    "href": "http://stock.jrj.com.cn/2021/12/27165434071105.shtml",
    "datetime": "2021-12-27 16:54:30",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：SSGJ-706注射液开展晚期实体瘤、复发/难治淋巴瘤的临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/12/27165234071099.shtml",
    "datetime": "2021-12-27 16:52:54",
    "code": "688336"
  },
  {
    "title": "三生国健（688336.SH）：“最具社会责任奖”得主，创新与使命齐头并进",
    "href": "http://stock.jrj.com.cn/2021/12/15084534017867.shtml",
    "datetime": "2021-12-15 08:45:53",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：选取NM28作为新型多特异抗体合作领域首个授权产品",
    "href": "http://stock.jrj.com.cn/2021/12/14172334014904.shtml",
    "datetime": "2021-12-14 17:23:57",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗IL-5人源化单克隆抗体注射液(610)Ib期临床试验完成首例受试者入组",
    "href": "http://stock.jrj.com.cn/2021/12/14172334014905.shtml",
    "datetime": "2021-12-14 17:23:45",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗PD-1人源化单克隆抗体注射液获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/11/24172333914708.shtml",
    "datetime": "2021-11-24 17:23:33",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗PD-1人源化单克隆抗体注射液获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/11/02172833803968.shtml",
    "datetime": "2021-11-02 17:28:46",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：抗IL-4Rα人源化单克隆抗体Ib期临床试验完成首例患者入组",
    "href": "http://stock.jrj.com.cn/2021/10/20165033722213.shtml",
    "datetime": "2021-10-20 16:50:26",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：双特异抗体SSGJ-706获得FDA批准进入临床I-II期",
    "href": "http://stock.jrj.com.cn/2021/10/18163833711173.shtml",
    "datetime": "2021-10-18 16:38:29",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：10天获得5张临床试验通知书",
    "href": "http://stock.jrj.com.cn/2021/10/08174833658376.shtml",
    "datetime": "2021-10-08 17:48:10",
    "code": "688336"
  },
  {
    "title": "三生国健：公司获得4项药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/10/08164933657983.shtml",
    "datetime": "2021-10-08 16:49:16",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：双特异抗体注射用SSGJ-705获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/29154533536448.shtml",
    "datetime": "2021-09-29 15:45:12",
    "code": "688336"
  },
  {
    "title": "【业绩会直击】三生国健（688336.SH）：成功扭亏为盈，创新研发取得突破性进展",
    "href": "http://stock.jrj.com.cn/2021/08/30180233353409.shtml",
    "datetime": "2021-08-30 18:02:18",
    "code": "688336"
  },
  {
    "title": "三生国健2021年半年度净利2242.31万元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2021/08/25203733318705.shtml",
    "datetime": "2021-08-25 20:37:40",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)上半年成功扭亏为盈 主力产品益赛普以价换量效果明显",
    "href": "http://stock.jrj.com.cn/2021/08/25201433318500.shtml",
    "datetime": "2021-08-25 20:14:53",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗IL-1β人源化单抗I期临床试验完成首例受试者入组",
    "href": "http://stock.jrj.com.cn/2021/08/19154733280351.shtml",
    "datetime": "2021-08-19 15:47:21",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗 IL-1β人源化单克隆抗体注射液临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/07/08174433064920.shtml",
    "datetime": "2021-07-08 17:44:51",
    "code": "688336"
  },
  {
    "title": "三生国健：双特异抗体SSGJ-705获得FDA批准进入临床I期",
    "href": "http://stock.jrj.com.cn/2021/06/15111132933375.shtml",
    "datetime": "2021-06-15 11:11:50",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：双特异抗体SSGJ-705获FDA批准进入临床I期",
    "href": "http://stock.jrj.com.cn/2021/06/14165732925601.shtml",
    "datetime": "2021-06-14 16:57:12",
    "code": "688336"
  },
  {
    "title": "三生国健（688336.SH）：“研产销一体化”优势获追捧，从Biotech走向Bio Pharma",
    "href": "http://stock.jrj.com.cn/2021/06/10104932904141.shtml",
    "datetime": "2021-06-10 10:49:27",
    "code": "688336"
  },
  {
    "title": "三生国健：公司重组抗VEGF人源化单克隆抗体pmCNV项目完成II期临床实验首例受试者入组",
    "href": "http://stock.jrj.com.cn/2021/06/08171032894194.shtml",
    "datetime": "2021-06-08 17:10:16",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗VEGF人源化单克隆抗体pmCNV项目完成II期临床实验首例受试者入组",
    "href": "http://stock.jrj.com.cn/2021/06/08162232893634.shtml",
    "datetime": "2021-06-08 16:22:45",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)拉升涨近10% 股价创4个月新高",
    "href": "http://stock.jrj.com.cn/2021/05/26103532821735.shtml",
    "datetime": "2021-05-26 10:35:31",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)拉升封涨停板 已连续第六日上涨",
    "href": "http://stock.jrj.com.cn/2021/05/18135432775512.shtml",
    "datetime": "2021-05-18 13:54:10",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗EGFR人鼠嵌合单克隆抗体注射液获批开展HER2阳性晚期结直肠癌临床试验",
    "href": "http://stock.jrj.com.cn/2021/05/12172432742784.shtml",
    "datetime": "2021-05-12 17:24:03",
    "code": "688336"
  },
  {
    "title": "三生国健：公司拥有18个处于不同开发阶段、涵盖肿瘤、自身免疫性及眼科等疾病领域的在研抗体药物",
    "href": "http://stock.jrj.com.cn/2021/05/10134432728610.shtml",
    "datetime": "2021-05-10 13:44:15",
    "code": "688336"
  },
  {
    "title": "三生国健：目前我们的临床管线中没有跟新冠相关的适应症在开发",
    "href": "http://stock.jrj.com.cn/2021/05/10131832728465.shtml",
    "datetime": "2021-05-10 13:18:45",
    "code": "688336"
  },
  {
    "title": "三生国健：注射用SSGJ-612将于近期开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/05/07105832706682.shtml",
    "datetime": "2021-05-07 10:58:02",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗IL-17A人源化单抗治疗中重度斑块状银屑病II期临试完成首例受试者入组",
    "href": "http://stock.jrj.com.cn/2021/04/21172332416895.shtml",
    "datetime": "2021-04-21 17:23:03",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重手投入研发，多管线并进",
    "href": "http://stock.jrj.com.cn/2021/04/12185332358876.shtml",
    "datetime": "2021-04-12 18:53:37",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)向139名激励对象授予224.35万股限制性股票",
    "href": "http://stock.jrj.com.cn/2021/04/08214832334214.shtml",
    "datetime": "2021-04-08 21:48:20",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)拟与宜明昂科合作开展赛普汀(伊尼妥单抗)联合IMM01临床研究",
    "href": "http://stock.jrj.com.cn/2021/04/07162732325549.shtml",
    "datetime": "2021-04-07 16:27:55",
    "code": "688336"
  },
  {
    "title": "三生国健2020年亏损2.17亿 总经理肖卫红薪酬387.46万",
    "href": "http://stock.jrj.com.cn/2021/03/31215432258649.shtml",
    "datetime": "2021-03-31 21:54:43",
    "code": "688336"
  },
  {
    "title": "三生国健：303项目开展的临床试验久远 经过审慎评估后 公司决定暂停该产品进一步开发",
    "href": "http://stock.jrj.com.cn/2021/03/10092932102028.shtml",
    "datetime": "2021-03-10 09:29:39",
    "code": "688336"
  },
  {
    "title": "三生国健：701项目公司已经停止继续进行",
    "href": "http://stock.jrj.com.cn/2021/03/09100532096314.shtml",
    "datetime": "2021-03-09 10:05:11",
    "code": "688336"
  },
  {
    "title": "三生国健：601A视网膜静脉阻塞项目II期临床实验首例受试者入组",
    "href": "http://stock.jrj.com.cn/2021/03/02104432055967.shtml",
    "datetime": "2021-03-02 10:44:06",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：重组抗VEGF人源化单抗RVO项目完成II期临床实验首例受试者入组",
    "href": "http://stock.jrj.com.cn/2021/03/01161332050536.shtml",
    "datetime": "2021-03-01 16:13:45",
    "code": "688336"
  },
  {
    "title": "三生国健2020年度亏损2亿由盈转亏 产品价格大幅下降",
    "href": "http://stock.jrj.com.cn/2021/02/26191032034652.shtml",
    "datetime": "2021-02-26 19:10:08",
    "code": "688336"
  },
  {
    "title": "上市半年业绩“大变脸”股价急坠破发 三生国健无法靠“王牌产品”躺赚怎么办？",
    "href": "http://stock.jrj.com.cn/2021/02/25072332022755.shtml",
    "datetime": "2021-02-25 07:23:54",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)拟推2021年限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2021/02/08191031871675.shtml",
    "datetime": "2021-02-08 19:10:07",
    "code": "688336"
  },
  {
    "title": "三生国健：公司面临的主要风险包括药企面临药物成本上升及药品降价的双重压力等",
    "href": "http://stock.jrj.com.cn/2021/01/26183831779196.shtml",
    "datetime": "2021-01-26 18:38:34",
    "code": "688336"
  },
  {
    "title": "三生国健：公司募投项目均按照计划顺利开展",
    "href": "http://stock.jrj.com.cn/2021/01/26164931777681.shtml",
    "datetime": "2021-01-26 16:49:13",
    "code": "688336"
  },
  {
    "title": "研发费用大幅增长 三生国健(688336.SH)2020年预亏1.94-2.24亿元",
    "href": "http://stock.jrj.com.cn/2021/01/20103131727242.shtml",
    "datetime": "2021-01-20 10:31:49",
    "code": "688336"
  },
  {
    "title": "新冠疫情、市场竞争等影响，三生国健2020年归母净利润预亏超1.94亿元",
    "href": "http://stock.jrj.com.cn/2021/01/19140331721534.shtml",
    "datetime": "2021-01-19 14:03:31",
    "code": "688336"
  },
  {
    "title": "三生国健2020年预计亏损1.94亿-2.24亿减少184.61%-197.69% 产品价格大幅下降",
    "href": "http://stock.jrj.com.cn/2021/01/18212831717262.shtml",
    "datetime": "2021-01-18 21:28:21",
    "code": "688336"
  },
  {
    "title": "创新研发投入加大，三生国健（688336.SH）是否被低估？",
    "href": "http://stock.jrj.com.cn/2021/01/18125631714552.shtml",
    "datetime": "2021-01-18 12:56:53",
    "code": "688336"
  },
  {
    "title": "三生国健募资17亿上市3个月后就破发 中信证券等承销",
    "href": "http://stock.jrj.com.cn/2021/01/13155731684207.shtml",
    "datetime": "2021-01-13 15:57:00",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：伊尼妥单抗新纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2020/12/28181231587353.shtml",
    "datetime": "2020-12-28 18:12:40",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：华泰证券首次覆盖给予“增持”评级，目标价32.5元(研报精要)",
    "href": "http://stock.jrj.com.cn/2020/12/18122731517653.shtml",
    "datetime": "2020-12-18 12:27:07",
    "code": "688336"
  },
  {
    "title": "三生国健(688336.SH)：选取Verseau的VSIG-4靶点抗体作为肿瘤免疫合作领域的第二个巨噬细胞检查点调节剂",
    "href": "http://stock.jrj.com.cn/2020/12/14185831488684.shtml",
    "datetime": "2020-12-14 18:58:19",
    "code": "688336"
  },
  {
    "title": "三生国健：611项目为中美双报 当前美国临床I期正在顺利开展中",
    "href": "http://stock.jrj.com.cn/2020/12/03140431399527.shtml",
    "datetime": "2020-12-03 14:04:39",
    "code": "688336"
  },
  {
    "title": "[三生国健]三生国健益赛普开启生物药“触手可及”新时代",
    "href": "http://stock.jrj.com.cn/2020/10/21000031105867.shtml",
    "datetime": "2020-10-21 00:00:00",
    "code": "688336"
  },
  {
    "title": "三生国健前三季度亏损5689.72万由盈转亏 销售收入下降",
    "href": "http://stock.jrj.com.cn/2020/10/19103831081898.shtml",
    "datetime": "2020-10-19 10:38:59",
    "code": "688336"
  },
  {
    "title": "三生国健：2020年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/10/19004031076666.shtml",
    "datetime": "2020-10-19 00:40:00",
    "code": "688336"
  },
  {
    "title": "三生国健：目前17个在研项目中有11项为肿瘤治疗药品，包括单克隆抗体和双抗",
    "href": "http://stock.jrj.com.cn/2020/10/09084231005023.shtml",
    "datetime": "2020-10-09 08:42:42",
    "code": "688336"
  },
  {
    "title": "（上市公司人事）三生国健副总经理倪华辞职",
    "href": "http://stock.jrj.com.cn/2020/09/24191630827242.shtml",
    "datetime": "2020-09-24 19:16:00",
    "code": "688336"
  },
  {
    "title": "核心药品独木难支 三生国健上市一个月业绩“变脸”",
    "href": "http://stock.jrj.com.cn/2020/09/07071730689389.shtml",
    "datetime": "2020-09-07 07:17:20",
    "code": "688336"
  },
  {
    "title": "三生国健上半年净利惨亏同比下降430% 现金流转负",
    "href": "http://stock.jrj.com.cn/2020/08/18164830530639.shtml",
    "datetime": "2020-08-18 16:48:00",
    "code": "688336"
  },
  {
    "title": "三生国健2020年上半年亏损5776.68万由盈转亏 持续加强研发项目投入",
    "href": "http://stock.jrj.com.cn/2020/08/18124130528840.shtml",
    "datetime": "2020-08-18 12:41:22",
    "code": "688336"
  },
  {
    "title": "三生国健今日科创板上市！现大涨102% 市值高达350亿元",
    "href": "http://stock.jrj.com.cn/2020/07/22102830312497.shtml",
    "datetime": "2020-07-22 10:28:55",
    "code": "688336"
  },
  {
    "title": "三生国健今日上市 发行价格28.18元/股",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/22091130311914.shtml",
    "datetime": "2020-07-22 09:11:51",
    "code": "688336"
  },
  {
    "title": "三生国健中签号出炉 中签号码共35315个",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/15082730246195.shtml",
    "datetime": "2020-07-15 08:27:50",
    "code": "688336"
  },
  {
    "title": "【兑奖啦】科创板三生国健网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/14190630240624.shtml",
    "datetime": "2020-07-14 19:06:54",
    "code": "688336"
  },
  {
    "title": "三生国健今日申购 顶格申购需配市值11.5万元",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/13081830221146.shtml",
    "datetime": "2020-07-13 08:18:35",
    "code": "688336"
  },
  {
    "title": "三生国健正式启动科创板IPO：主力产品面临专利保护到期",
    "href": "http://stock.jrj.com.cn/kcb/2020/07/04090430138823.shtml",
    "datetime": "2020-07-04 09:04:20",
    "code": "688336"
  },
  {
    "title": "三生国健IPO正式启动",
    "href": "http://stock.jrj.com.cn/2020/07/03124830132599.shtml",
    "datetime": "2020-07-03 12:48:00",
    "code": "688336"
  },
  {
    "title": "三生国健3日起招股 将登陆科创板",
    "href": "http://stock.jrj.com.cn/2020/07/02215230125595.shtml",
    "datetime": "2020-07-02 21:52:09",
    "code": "688336"
  },
  {
    "title": "三生国健IPO：关联服务费陡增800万元疑输送利益 经营指标恶化仍靠一款产品“打天下”",
    "href": "http://stock.jrj.com.cn/2020/06/01073329812787.shtml",
    "datetime": "2020-06-01 07:33:00",
    "code": "688336"
  },
  {
    "title": "三生国健过会：今年科创板过会第29家 华泰联合过5单",
    "href": "http://stock.jrj.com.cn/2020/05/12095829648084.shtml",
    "datetime": "2020-05-12 09:58:00",
    "code": "688336"
  },
  {
    "title": "三生国健科创板过会：单一产品益赛普单价下降 收入增速缓慢",
    "href": "http://stock.jrj.com.cn/kcb/2020/05/12093629647614.shtml",
    "datetime": "2020-05-12 09:36:55",
    "code": "688336"
  },
  {
    "title": "三生国健净利下滑产能利用率低 外籍实控人拟募32亿",
    "href": "http://stock.jrj.com.cn/2020/05/06070229595096.shtml",
    "datetime": "2020-05-06 07:02:00",
    "code": "688336"
  },
  {
    "title": "三生国健哮喘新药临床试验获批",
    "href": "http://stock.jrj.com.cn/2020/02/25224628892772.shtml",
    "datetime": "2020-02-25 22:46:40",
    "code": "688336"
  },
  {
    "title": "三生国健：国内TNF-a抑制剂市场前景广阔 主打产品保持领先地位",
    "href": "http://stock.jrj.com.cn/2019/11/19184228419917.shtml",
    "datetime": "2019-11-19 18:42:47",
    "code": "688336"
  },
  {
    "title": "三生国健“单兵作战”存隐忧 营业收入勾稽有异常",
    "href": "http://stock.jrj.com.cn/kcb/2019/11/09094628374606.shtml",
    "datetime": "2019-11-09 09:46:15",
    "code": "688336"
  },
  {
    "title": "三生国健冲刺科创板 主打产品益赛普国内市场份额逾五成",
    "href": "http://stock.jrj.com.cn/kcb/2019/11/05054328351125.shtml",
    "datetime": "2019-11-05 05:43:27",
    "code": "688336"
  },
  {
    "title": "港股分拆上市又一家 三生国健科创板申请获受理",
    "href": "http://stock.jrj.com.cn/2019/10/31174428334414.shtml",
    "datetime": "2019-10-31 17:44:54",
    "code": "688336"
  }
]